ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Many investors have flocked to buy Daiichi Sankyo shares following the successful launch of its Enhertu cancer treatment that mainly targets breast cancer and is widely expected to become a global blockbuster. (Nikkei montage)
Business Spotlight

Daiichi Sankyo: Drugmaker roars back to health with cancer success

After Ranbaxy debacle, Japanese company charts new path with focus on R&D

MITSURU OBE, Nikkei staff writer | Japan

TOKYO -- Until just several years ago, pharmaceutical manufacturer Daiichi Sankyo was one of the most unpopular public companies among investors in Japan, rocked by an internal feud and reeling from a disastrous acquisition in India. But it has roared back and is now one of the country's most valuable corporations.

With its market capitalization hitting 8.2 trillion yen ($78.9 billion) in late November -- the highest since the company's creation through a merger between two Japanese drugmakers in 2005 -- it is now ahead of Takeda Pharmaceutical, the sector's revenue leader in Japan, and competes with Chugai Pharmaceutical, a unit of Switzerland's Roche, for the title of the most valuable such corporation in Japan.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more